A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm^2 and up to 100 cm^2 in Adult Patients With Actinic Keratosis
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Tirbanibulin (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors Almirall S.A.
Most Recent Events
- 10 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Nov 2026.
- 31 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Apr 2026.